EGFR and non-small cell lung carcinoma: The most common activating mutations of EGFR in NSCLC (approximately 85%) include exon 19 deletions and a point mutation on exon 21 (Leu858Arg, L858A), known as sensitizing mutations, which are responsible for oral TKIs targeting EGFR.